Alzheimer's disease (AD) is the commonest cause of dementia affecting older people, and is associated with loss of cholinergic neurons in parts of the brain subserving aspects of memory. Acetylcholinesterase inhibitors, such as rivastigmine, delay the breakdown of acetylcholine released into synaptic clefts and may enhance cholinergic neurotransmission. There is evidence that rivastigmine is beneficial for people with Alzheimer's disease, in being associated with small improvements in the rate of decline of cognitive function and activities of daily living. Adverse effects were consistent with the cholinergic actions of the drug.
Rivastigmine is beneficial for people with Alzheimer's disease
8 July 2009
This record should be cited as:
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.pub2
Assessed as up to date:
9 September 2008
More like this
- Cholinesterase inhibitors (ChEIs), donepezil, galantamine and rivastigmine are efficacious for mild to moderate Alzheimer's disease
- Donepezil is beneficial for people with mild, moderate and severe dementia due to Alzheimer's disease
- Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD
- Velnacrine is not beneficial for people with Alzheimer's disease
- There is currently insufficient evidence of the effects of Huperzine A for Alzheimer's disease (AD).